Search

Your search keyword '"Schönland S"' showing total 296 results
Start Over Author "Schönland S"

Refine your results

more »

more »

more »

more »
296 results on '"Schönland S"'

3. P56 SURVIVAL BENEFIT OF BIRTAMIMAB IN MAYO STAGE IV AL AMYLOIDOSIS IN THE PHASE 3 VITAL STUDY WAS CONSISTENT ACROSS ALL KEY BASELINE VARIABLES

Author

Gertz, M., primary, Cohen, A., additional, Comenzo, R., additional, Kastritis, E., additional, Landau, H., additional, Libby, E., additional, Liedtke, M., additional, Sanchorawala, V., additional, Schönland, S., additional, Wechalekar, A., additional, Ando, Y., additional, Koh, Y., additional, Zonder, J., additional, Palladini, G., additional, Nie, C., additional, Karp, C., additional, Jin, Y., additional, Conrad, A., additional, Kinney, G., additional, and Merlini, G., additional

Published
2023
Full Text
View/download PDF

4. An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMT

Author

Beksac, M., Iacobelli, S., Koster, Linda (Extern), Cornelissen, J, Griskevicius, L., Rabin, N.K., Stoppa, A.M., Meijer, E., Mear, J.B., Zeerleder, S., Mayer, J., Fenk, R., Fegueux, N., Chevallier, P., Konirova, E., Snowden, J.A., Engelhardt, M., Orchard, K., Hulin, C., Schaap, N.P., Sossa, C., Elmaagacli, A., McLornan, D.P., Hayden, P.J., Schönland, S., Yakoub-Agha, I., Beksac, M., Iacobelli, S., Koster, Linda (Extern), Cornelissen, J, Griskevicius, L., Rabin, N.K., Stoppa, A.M., Meijer, E., Mear, J.B., Zeerleder, S., Mayer, J., Fenk, R., Fegueux, N., Chevallier, P., Konirova, E., Snowden, J.A., Engelhardt, M., Orchard, K., Hulin, C., Schaap, N.P., Sossa, C., Elmaagacli, A., McLornan, D.P., Hayden, P.J., Schönland, S., and Yakoub-Agha, I.

Abstract

Item does not contain fulltext, Early relapse (ER) following Autologous Hematopoietic Cell Transplantation (AHCT) confers a poor prognosis. We therefore developed a novel scoring system to predict ER. A total of 14,367 AHCT-1 patients were transplanted between 2014 and 2019, and were conditioned with Melphalan 200 mg/m(2) (Mel200) (n = 7228; 2014-2017) (training cohort); Mel200 (n = 5616; 2018-2019) or Mel140 (n = 1523; 2018-2019) (validation cohorts). PFS-12 and the Cumulative Incidence of Relapse at 12 months were 84.1% and 14.7% (training Mel200), 87.2% and 11.6% (validation Mel200), and 80.3% and 16.9% (validation Mel140), respectively. The points in the risk score were: 0, 1,2 for ISS stages I, II, and III; Disease status: 0 (CR/VGPR); 1 (PR); 2 (SD/MR); 4 (Relapse/Progression); and 1 for Karnofsky ≤ 70. The distribution of scores: 0 (24%), 1 (33.9%), 2 (29.6 %), 3 (9.5%), and ≥4 (2.7%). The score separated PFS-12, with the lowest risk group (n = 1752) having a PFS-12 of 91.7% and the highest risk group (n = 195) 57.1%. This also applied in cytogenetically high-risk patients. If the pre-score baseline risks are 15% (standard risk) and 25% (high-risk), a score of ≥4 confers calculated risks of 38% and 54%, respectively. This novel EBMT ER score, therefore, allows for the identification of five discrete prognostic groups.

Published
2023

5. Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: comparison with myeloma

Author

da Silva Filho, M I, Försti, A, Weinhold, N, Meziane, I, Campo, C, Huhn, S, Nickel, J, Hoffmann, P, Nöthen, M M, Jöckel, K-H, Landi, S, Mitchell, J S, Johnson, D, Morgan, G J, Houlston, R, Goldschmidt, H, Jauch, A, Milani, P, Merlini, G, Rowcieno, D, Hawkins, P, Hegenbart, U, Palladini, G, Wechalekar, A, Schönland, S O, and Hemminki, K

Published
2017
Full Text
View/download PDF

7. Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation

Author

van Gelder, M, de Wreede, L C, Bornhäuser, M, Niederwieser, D, Karas, M, Anderson, N S, Gramatzki, M, Dreger, P, Michallet, M, Petersen, E, Bunjes, D, Potter, M, Beelen, D, Cornelissen, J J, Yakoub-Agha, I, Russell, N H, Finke, J, Schoemans, H, Vitek, A, Urbano-Ispízua, Á, Blaise, D, Volin, L, Chevallier, P, Caballero, D, Putter, H, van Biezen, A, Henseler, A, Schönland, S, Kröger, N, and Schetelig, J

Published
2017
Full Text
View/download PDF

8. The impact of allogeneic stem cell transplantation on the natural course of poor-risk chronic lymphocytic leukemia as defined by the EBMT consensus criteria: a retrospective donor versus no donor comparison

Author

Herth, I., Dietrich, S., Benner, A., Hegenbart, U., Rieger, M., Stadtherr, P., Bondong, A., Tran, T.H., Weide, R., Hensel, M., Knauf, W., Franz-Werner, J., Welslau, M., Procaccianti, M., Görner, M., Meissner, J., Luft, T., Schönland, S., Witzens-Harig, M., Zenz, T., Ho, A.D., and Dreger, P.

Published
2014
Full Text
View/download PDF

9. Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party

Author

Sobh, M, Michallet, M, Gahrton, G, Iacobelli, S, van Biezen, A, Schönland, S, Petersen, E, Schaap, N, Bonifazi, F, Volin, L, Meijer, E, Niederwieser, D, El-Cheikh, J, Tabrizi, R, Fegeux, N, Finke, J, Bunjes, D, Cornelissen, J, Einsele, H, Bruno, B, Potter, M, Fanin, R, Mohty, M, Garderet, L, and Kröger, N

Published
2016
Full Text
View/download PDF

12. P1714: HEALTHCARE RESOURCE UTILIZATION IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS IN EUROPE

Author

Jaccard, A., primary, Bridoux, F., additional, Roeloffzen, W., additional, Minnema, M. C., additional, Bergantim, R., additional, Hájek, R., additional, João, C., additional, Cibeira, M. T., additional, Palladini, G., additional, Schönland, S., additional, Merlini, G., additional, Milani, P., additional, Dimopoulos, M. A., additional, Ravichandran, S., additional, Hegenbart, U., additional, Agis, H., additional, Gros, B., additional, Asra, A., additional, Dergarabetian, E., additional, Magarotto, V., additional, Leonidakis, A., additional, Cheliotis, G., additional, Sonneveld, P., additional, Wechalekar, A., additional, and Kastritis, E., additional

Published
2022
Full Text
View/download PDF

13. P957: CARFILZOMIB, LENALIDOMIDE, DEXAMETHASONE FOLLOWED BY A SECOND AUTO-HCT IS AN EFFECTIVE STRATEGY IN FIRST RELAPSE MULTIPLE MYELOMA: A STUDY OF THE CHRONIC MALIGNANCIES WORKING PARTY OF EBMT

Author

Tilmont, R., primary, Yakoub-Agha, I., additional, Eikema, D.-J., additional, Zinger, N., additional, Haenel, M., additional, Schaap, N., additional, Herrera Arroyo, C., additional, Schuermans, C., additional, Bethge, W., additional, Engelhardt, M., additional, Kuball, J., additional, Michieli, M., additional, Schub, N., additional, Wilson, K. M. O., additional, Bourhis, J. H., additional, Mateos, M. V., additional, Robin, N., additional, Jost, E., additional, Kröger, N., additional, Moraleda, J. M., additional, Sica, S., additional, Hayden, P. J., additional, Beksac, M., additional, Schönland, S., additional, and Manier, S., additional

Published
2022
Full Text
View/download PDF

14. P914: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK

Author

Kastritis, E., primary, Palladini, G., additional, Dimopoulos, M. A., additional, Jaccard, A., additional, Merlini, G., additional, Theodorakakou, F., additional, Fotiou, D., additional, Minnema, M. C., additional, Wechalekar, A., additional, Gkolfinopoulos, S., additional, Manousou, K., additional, Sonneveld, P., additional, and Schönland, S., additional

Published
2022
Full Text
View/download PDF

15. Allogeneic hematopoietic stem cell transplantation for adult HLH: a retrospective study by the chronic malignancies and inborn errors working parties of EBMT

Author

Machowicz, R., Suarez, F., Wiktor-Jedrzejczak, W., Eikema, D.J., Wreede, L.C. de, Blok, H.J., Isaksson, C., Einsele, H., Poiré, X., Dorp, S. van, Nikolousis, E., Johansson, J.E., Kobbe, G., Zecca, M., Arnold, R., Gerbitz, A., Finke, J., Díez-Martín, J.L., Bonifazi, F., McQuaker, G., Lenhoff, S., Rohrlich, P.S., Theobald, M., Ljungman, P., Collin, M., Albert, M.H., Ehninger, G., Carlson, K., Halaburda, K., Lehmberg, K., Schönland, S., Yakoub-Agha, I., Gennery, A.R., Lankester, A.C., Kröger, N., Machowicz, R., Suarez, F., Wiktor-Jedrzejczak, W., Eikema, D.J., Wreede, L.C. de, Blok, H.J., Isaksson, C., Einsele, H., Poiré, X., Dorp, S. van, Nikolousis, E., Johansson, J.E., Kobbe, G., Zecca, M., Arnold, R., Gerbitz, A., Finke, J., Díez-Martín, J.L., Bonifazi, F., McQuaker, G., Lenhoff, S., Rohrlich, P.S., Theobald, M., Ljungman, P., Collin, M., Albert, M.H., Ehninger, G., Carlson, K., Halaburda, K., Lehmberg, K., Schönland, S., Yakoub-Agha, I., Gennery, A.R., Lankester, A.C., and Kröger, N.

Abstract

Item does not contain fulltext, Hemophagocytic lymphohistiocytosis (HLH; hemophagocytic syndrome) is a rare syndrome of potentially fatal, uncontrolled hyperinflammation. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is indicated in primary, recurrent or progressive HLH, but information about its outcomes in the adult population is limited. We obtained data about 87 adult (≥18 years of age) patients retrospectively reported to the EBMT. The median survival time was 13.9 months. The three and five-year overall survival (OS) was 44% (95% CI 33-54%). Among 39 patients with a follow-up longer than 15 months, only three died. Relapse rate was 21% (95% CI 13-30%), while NRM reached 36% (95% CI 25-46%). Younger patients (<30 years of age) had better prognosis, with an OS of 59% (95% CI 45-73%) at three and five years vs 23% (95% CI 8-37%) for older ones. No difference in survival between reduced and myeloablative conditioning was found. To our knowledge, this is the largest report of adult HLH patients who underwent allo-HSCT. Patients who survive the first period after this procedure can expect a long disease-free survival. Both reduced intensity and myeloablative conditioning have therapeutic potential in adult HLH.

Published
2022

20. Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA study

Author

Sanchorawala, V. Palladini, G. Minnema, M.C. Jaccard, A. Lee, H.C. Gibbs, S. Mollee, P. Venner, C. Lu, J. Schönland, S. Gatt, M. Suzuki, K. Kim, K. Cibeira, M.T. Beksac, M. Libby, E. Valent, J. Hungria, V. Wong, S.W. Rosenzweig, M. Bumma, N. Chauveau, D. Gries, K.S. Fastenau, J. Tran, N.P. Qin, X. Vasey, S.Y. Weiss, B.M. Vermeulen, J. Ho, K.F. Merlini, G. Comenzo, R.L. Kastritis, E. Wechalekar, A.D.

Subjects
endocrine system, humanities
Abstract

In the phase 3 ANDROMEDA trial, patients treated with daratumumab, bortezomib, cyclophosphamide, and dexamethasone (D-VCd) had significantly higher rates of organ and hematologic response compared with patients who received VCd alone. Here, we present patient-reported outcomes (PROs) from the ANDROMEDA trial. PROs were assessed through cycle 6 using three standardized questionnaires. Treatment effect through cycle 6 was measured by a repeated-measures, mixed-effects model. The magnitude of changes in PROs versus baseline was generally low, but between-group differences favored the D-VCd group. Results were generally consistent irrespective of hematologic, cardiac, or renal responses. More patients in the D-VCd group experienced meaningful improvements in PROs; median time to improvement was more rapid in the D-VCd group versus the VCd group. After cycle 6, patients in the D-VCd group received daratumumab monotherapy and their PRO assessments continued, with improvements in health-related quality of life (HRQoL) reported through cycle 19. PROs of subgroups with renal and cardiac involvement were consistent with those of the intent-to-treat population. These results demonstrate that the previously reported clinical benefits of D-VCd were achieved without decrement to patients' HRQoL and provide support of D-VCd in patients with AL amyloidosis. © 2022 Wiley Periodicals LLC.

Published
2022

23. Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous transplantation: a study by the European Group for Blood and Marrow Transplantation

Author

Auner, H W, Szydlo, R, van Biezen, A, Iacobelli, S, Gahrton, G, Milpied, N, Volin, L, Janssen, J, Nguyen Quoc, S, Michallet, M, Schoemans, H, el Cheikh, J, Petersen, E, Guilhot, F, Schönland, S, Ahlberg, L, Morris, C, Garderet, L, de Witte, T, and Kröger, N

Published
2013
Full Text
View/download PDF

24. Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party

Author

Hayden, P.J., Eikema, D.J., Wreede, L.C. de, Koster, L, Kröger, N., Einsele, H., Minnema, M., Dominietto, A., Potter, M., Passweg, J., Bermúdez, A., Nguyen-Quoc, S., Platzbecker, U., Tischer, J., Ciceri, F., Veelken, J.H., Ljungman, P., Schaap, N.P., Forcade, E., Carella, A.M., Gandemer, V., Arcese, W., Bloor, A., Olivieri, A., Vincent, L., Beksac, M., Schönland, S., Yakoub-Agha, I., Hayden, P.J., Eikema, D.J., Wreede, L.C. de, Koster, L, Kröger, N., Einsele, H., Minnema, M., Dominietto, A., Potter, M., Passweg, J., Bermúdez, A., Nguyen-Quoc, S., Platzbecker, U., Tischer, J., Ciceri, F., Veelken, J.H., Ljungman, P., Schaap, N.P., Forcade, E., Carella, A.M., Gandemer, V., Arcese, W., Bloor, A., Olivieri, A., Vincent, L., Beksac, M., Schönland, S., and Yakoub-Agha, I.

Abstract

Contains fulltext : 244085.pdf (Publisher’s version ) (Open Access), The EBMT Chronic Malignancies Working Party performed a retrospective analysis of 215 patients who underwent a second allo-HCT for myeloma between 1994 and 2017, 159 for relapse and 56 for graft failure. In the relapse group, overall survival (OS) was 38% (30-46%) at 2 years and 25% (17-32%) at 5 years. Patients who had a HLA-identical sibling (HLAid-Sib) donor for their first and second transplants had superior OS (5 year OS: HLAid-Sib/HLAid-Sib: 35% (24-46%); Others 9% (0-17%), p < 0.001). There was a significantly higher incidence of acute grade II-IV GvHD in those patients who had also developed GvHD following their initial HLA-identical sibling allo-HCT (HLAid-Sib/HLAid-Sib: 50% (33-67%); Other 22% (8-36%), p = 0.03). More as opposed to fewer than 2 years between transplants was associated with superior 5-yr OS (31% (21-40%) vs. 10% (1-20%), P = 0.005). On multivariate analysis, consecutive HLA-identical sibling donor transplants conferred a significant OS advantage (0.4 (0.24-0.67), p < 0.001). In the graft failure group, OS was 41% at 2 years. In summary, a second allo-HCT using a HLA-identical sibling donor, if available, provides the best transplant outcomes for relapsed myeloma in this setting.

Published
2021

32. Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID-19 pandemic

Author

Kastritis, E. Wechalekar, A. Schönland, S. Sanchorawala, V. Merlini, G. Palladini, G. Minnema, M. Roussel, M. Jaccard, A. Hegenbart, U. Kumar, S. Cibeira, M.T. Blade, J. Dimopoulos, M.A.

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-associated coronavirus disease 2019 (COVID-19) is primarily manifested as a respiratory tract infection, but may affect and cause complications in multiple organ systems (cardiovascular, gastrointestinal, kidneys, haematopoietic and immune systems), while no proven specific therapy exists. The challenges associated with COVID-19 are even greater for patients with light chain (AL) amyloidosis, a rare multisystemic disease affecting the heart, kidneys, liver, gastrointestinal and nervous system. Patients with AL amyloidosis may need to receive chemotherapy, which probably increases infection risk. Management of COVID-19 may be particularly challenging in patients with AL amyloidosis, who often present with cardiac dysfunction, nephrotic syndrome, neuropathy, low blood pressure and gastrointestinal symptoms. In addition, patients with AL amyloidosis may be more susceptible to toxicities of drugs used to manage COVID-19. Access to health care may be difficult or limited, diagnosis of AL amyloidosis may be delayed with detrimental consequences and treatment administration may need modification. Both patients and treating physicians need to adapt in a new reality. © 2020 British Society for Haematology and John Wiley & Sons Ltd

Published
2020

34. Essays upon heredity and kindred biological problems

Author

Weismann, August, 1834-1914, Poulton, Edward Bagnall, Sir, 1856-1943, Schönland, S. 1860, Shipley, A. E. Sir, (Arthur Everett), 1861-1927, King's College London, King's College London, Foyle Special Collections Library (archive.org), Weismann, August, 1834-1914, Poulton, Edward Bagnall, Sir, 1856-1943, Schönland, S. 1860, Shipley, A. E. Sir, (Arthur Everett), 1861-1927, and King's College London

Subjects
Electronic books, Genetics, Heredity, Reproduction
Published
1889

35. Essays upon heredity and kindred biological problems, by Dr. August Weismann ... Ed. by Edward B. Poulton ... Selmar Schönland ... and Arthur E. Shipley...Authorised translation.

Author

Weismann, August, 1834-1914, Poulton, Edward Bagnall, Sir, 1856-1943, Schönland, S. 1860, Shipley, A. E. Sir, (Arthur Everett), 1861-1927, Wellesley College Library (archive.org), Weismann, August, 1834-1914, Poulton, Edward Bagnall, Sir, 1856-1943, Schönland, S. 1860, and Shipley, A. E. Sir, (Arthur Everett), 1861-1927

Subjects
Evolution, Heredity, Reproduction
Published
1891

36. Essays upon heredity and kindred biological problems, by Dr. August Weismann. Ed. by Edward B. Poulton, Selmar Schönland, and Arthur E. Shipley. Authorised translation

Author

Weismann, August, 1834-1914, Poulton, Edward Bagnall, Sir, 1856-1943, Schönland, S. 1860, Shipley, A. E. Sir, (Arthur Everett), 1861-1927, MBLWHOI Library, NCSU Libraries (archive.org), Princeton Theological Seminary Library (archive.org), Weismann, August, 1834-1914, Poulton, Edward Bagnall, Sir, 1856-1943, Schönland, S. 1860, and Shipley, A. E. Sir, (Arthur Everett), 1861-1927

Subjects
Evolution, Heredity, Reproduction
Published
1891

37. Essays upon heredity and kindred biological problems / By August Weismann. Authorized translation edited by Edward B. Poulton, Selmar Schönland, and Arthur E. Shipley.

Author

Weismann, August, 1834-1914, Poulton, Edward Bagnall, Sir, 1856-1943, Schönland, S. 1860, Shipley, A. E. Sir, (Arthur Everett), 1861-1927, MBLWHOI Library, Weismann, August, 1834-1914, Poulton, Edward Bagnall, Sir, 1856-1943, Schönland, S. 1860, and Shipley, A. E. Sir, (Arthur Everett), 1861-1927

Subjects
Evolution, Heredity, Reproduction
Published
1889

38. Essays upon heredity and kindred biological problems

Author

Weismann, August, 1834-1914, Poulton, Edward Bagnall, Sir, 1856-1943, Schönland, S. 1860, Shipley, A. E. Sir, (Arthur Everett), 1861-1927, MBLWHOI Library, Weismann, August, 1834-1914, Poulton, Edward Bagnall, Sir, 1856-1943, Schönland, S. 1860, and Shipley, A. E. Sir, (Arthur Everett), 1861-1927

Subjects
Evolution, Heredity, Reproduction

40. Essays upon heredity and kindred biological problems, by Dr. August Weismann. Ed. by Edward B. Poulton, Selmar Schönland, and Arthur E. Shipley. Authorised translation

Author

Weismann, August, 1834-1914, Poulton, Edward Bagnall, Sir, 1856-1943, Schönland, S. 1860, Shipley, A. E. Sir, (Arthur Everett), 1861-1927, Princeton Theological Seminary Library (archive.org), Weismann, August, 1834-1914, Poulton, Edward Bagnall, Sir, 1856-1943, Schönland, S. 1860, and Shipley, A. E. Sir, (Arthur Everett), 1861-1927

Subjects
Evolution, Heredity, Reproduction

41. Essays upon heredity and kindred biological problems, by Dr. August Weismann. Ed. by Edward B. Poulton, Selmar Schönland, and Arthur E. Shipley. Authorised translation

Author

Weismann, August, 1834-1914, Poulton, Edward Bagnall, Sir, 1856-1943, Schönland, S. 1860, Shipley, A. E. Sir, (Arthur Everett), 1861-1927, Princeton Theological Seminary Library (archive.org), Weismann, August, 1834-1914, Poulton, Edward Bagnall, Sir, 1856-1943, Schönland, S. 1860, and Shipley, A. E. Sir, (Arthur Everett), 1861-1927

Subjects
Evolution, Heredity, Reproduction

43. Tandem autologous/reduced-intensity allogeneic stem cell transplantation versus autologous transplantation in multiple myeloma - update of the EBMT-NMAM2000 study at 96 months median follow-up: 197

Author

Gahrton, G., Iacobelli, S., Björkstrand, B., Hegenbart, U., Gruber, A., Greinix, H., Volin, L., Narni, F., Carella, A., Beksac, M., Bosi, A., Milone, G., Corradini, P., Schönland, S., Friberg, K., van Biezen, A., Goldschmidt, H., de Witte, T., Morris, C., Niederwieser, D., Garderet, L., and Kröger, N.

Published
2013

44. Higher probability of survival in complete remission following tandem autologous/reduced-intensity allogeneic transplantation compared to autologous transplantation alone in the NMAM2000 multiple myeloma trial as estimated by multistate models: O158

Author

Iacobelli, S., De Wreede, L., Björkstrand, B., Hegenbart, U., Gruber, A., Greinix, H., Volin, L., Narni, F., Carella, A. M., Beksac, M., Bosi, A., Milone, G., Corradini, P., Schönland, S., Friberg, K., van Biezen, A., Goldschmidt, H., de Witte, T., Morris, C., Niederwieser, D., Garderet, L., Kröger, N., and Gahrton, G.

Published
2013

Catalog

Books, media, physical & digital resources
See catalog results